Dyskinesia, Drug-Induced
Information
- Disease name
- Dyskinesia, Drug-Induced
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00255879 | Completed | Phase 1 | Movement Disorders Caused by Antipsychotic Drugs in Older Patients | January 1999 | August 2004 |
| NCT01173731 | Completed | Phase 2 | Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias | October 2010 | October 2013 |
| NCT03354455 | Completed | N/A | Investigating the Causal Role of preSMA in Levodopa-induced Dyskinesia in Parkinson's Disease | August 1, 2017 | September 16, 2018 |
| NCT04064294 | Recruiting | Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors | June 1, 2019 | March 31, 2027 | |
| NCT00686699 | Terminated | Phase 2 | Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628) | July 10, 2006 | March 6, 2008 |
| NCT04857359 | Unknown status | Phase 2/Phase 3 | Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy | August 6, 2021 | August 2023 |
| NCT05116813 | Unknown status | Phase 2/Phase 3 | Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy | October 25, 2021 | December 2023 |
| NCT00837707 | Unknown status | Phase 4 | Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia | June 2008 | February 2010 |
| NCT03987750 | Withdrawn | Phase 3 | Safinamide for Levodopa-induced Dyskinesia (PD-LID) | October 2019 | May 2021 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D004409